150 related articles for article (PubMed ID: 1973061)
1. The immunologic detection of minimal residual disease in acute leukemia.
Campana D; Coustan-Smith E; Janossy G
Blood; 1990 Jul; 76(1):163-71. PubMed ID: 1973061
[TBL] [Abstract][Full Text] [Related]
2. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases.
Janossy G; Coustan-Smith E; Campana D
Leukemia; 1989 Mar; 3(3):170-81. PubMed ID: 2465463
[TBL] [Abstract][Full Text] [Related]
3. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
4. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens.
Syrjälä M; Anttila VJ; Ruutu T; Jansson SE
Leukemia; 1994 Sep; 8(9):1564-70. PubMed ID: 7522295
[TBL] [Abstract][Full Text] [Related]
6. The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study.
Campana D; Yokota S; Coustan-Smith E; Hansen-Hagge TE; Janossy G; Bartram CR
Leukemia; 1990 Sep; 4(9):609-14. PubMed ID: 1975635
[TBL] [Abstract][Full Text] [Related]
7. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
8. Cellular characteristics of acute leukemia cells simultaneously expressing CD13/CD33, CD7 and CD19.
Mizutani M; Miwa H; Takahashi T; Katoh K; Shikami M; Katayama N; Shiku H; Kita K
Int J Hematol; 1997 Dec; 66(4):479-91. PubMed ID: 9479874
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of CD13 and CD33 expression at relapse on acute myeloid leukemia cells with an unusual phenotype: MPO+CD13-CD33-.
Kawada H; Ichikawa Y; Kobayashi N; Fukuda R; Yonekura S; Nagao T
Intern Med; 1993 Sep; 32(9):733-6. PubMed ID: 7908235
[TBL] [Abstract][Full Text] [Related]
10. Enhanced myeloid specificity of CD117 compared with CD13 and CD33.
Nomdedéu JF; Mateu R; Altès A; Llorente A; Rio C; Estivill C; López O; Ubeda J; Rubiol E
Leuk Res; 1999 Apr; 23(4):341-7. PubMed ID: 10229319
[TBL] [Abstract][Full Text] [Related]
11. [Immunologic classification used in typing of 68 cases of acute leukemias].
Sun XL; Fang MY; Jiang F; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):39-41. PubMed ID: 16584588
[TBL] [Abstract][Full Text] [Related]
12. [CD13- and CD33-negative acute myelocytic leukemia (FAB classification; M2) with morphological changes and CD13 expression on recurrence].
Aoyama Y; Yamane T; Kanashima H; Takeoka Y; Koh K; Nakao Y; Yamamura R; Nakamae H; Ohta K; Inoue T; Hino M; Tatsumi N
Rinsho Ketsueki; 2001 Apr; 42(4):314-20. PubMed ID: 11400303
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic heterogeneity of TDT+ cells in the blood and bone marrow: implications for surveillance of residual leukemia.
Smith RG; Kitchens RL
Blood; 1989 Jul; 74(1):312-9. PubMed ID: 2473798
[TBL] [Abstract][Full Text] [Related]
14. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
Drach J; Drach D; Glassl H; Gattringer C; Huber H
Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
18. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
19. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Jun; 42(1-2):75-82. PubMed ID: 11699224
[TBL] [Abstract][Full Text] [Related]
20. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
